The Association of Diversity in Clinical Trials (AOD) has announced a new partnership agreement with Black Women in Clinical Research (BWICR) allowing their 15,000 members an opportunity to participate in AOD benefits. The mission of the AOD is to establish standards and best practices for the clinical trials industry to improve the representation of diverse participants in clinical trials through the development, integration, and monitoring of quality and consistent diversity methodology across the research industry.
Danielle Mitchell, CEO of BWICR, stated, "The mission of the AOD meets our corporate goals in being a part of standardizing best practices for professionals and bringing training and certification forward in a structured and accessible way for our members. This commitment is exciting and will bring value to our industry as a whole."
Diana Foster, PhD, president of the AOD, credits Mitchell's story of having been blocked from entry into clinical research as the impetus behind her organization's mission.
BLACK WOMEN IN CLINICAL RESEARCH JOINS THE ASSOCIATION OF DIVERSITY IN CLINICAL TRIALS AS A SUPPORTING PARTNER BRINGING 15,000 MEMBERS TO PARTICIPATE IN AOD MEMBERSHIP. (2023, June 21). Cision PR Newswire.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.